検索画面
細胞材料開発室サイト

戻る 戻る
細胞材料の再培養方法 ( HPS以外・ HPS )
細胞番号 : 細胞名
RCB5685 : MDS-L  update : 2025/03/20
細胞特性(Comment:英)
細胞特性(日)
細胞特性(寄託者記述:英)MDS-L cell line is a blastic subline originated from MDS92 which was established from the bone marrow of a patient with MDS. MDS-L cells proliferate in the presence of IL-3 and have lost maturing capacity unlike the parental MDS92. MDS-L is a parental cell line of MDS-L-2007 and MDS-LGF.
細胞特性(寄託者記述:日)骨髄異形成症候群（MDS）患者骨髄由来の細胞株であるMDS92の培養中に出現した亜株である。IL-3依存性に増殖し、主に幼若芽球様細胞から成る。MDS-L-2007, MDS-LGFの元となった細胞株である。
使用条件(英)1) TheRECIPIENT of BIOLOGICAL RESOURCE shall obtain a priorcon sent on use of it from the DEVELOPER and DEPOSITOR. The RECIPIENT shall conclude a MTA with the depositor. 2) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature (Leukemia 2018 32(8):1846-1850) designated by the DEPOSITOR is requested. 3) In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
使用条件(日)1) 研究責任者と寄託者間で事前に承諾を得る。寄託者とMTAを締結する。2) 研究成果の公表にあたって寄託者の指定する文献 (Leukemia 2018 32(8):1846-1850) を引用すること。3) 研究成果の公表にあたって謝辞の表明を必要とする。
備考(英)
備考(日)
承諾者住所
×
Japanese
住所
701-0192 岡山県 倉敷市松島577番地
産学連携知的財産管理室
E-mail. s-renkei@med.kawasaki-m.ac.jp

English
Address
Kawasaki University of Medical Welfare
Industry-Academia Collaboration and Intellectual Property Management Section
577 Matsushima, Kurashiki-city, Okayama 701-0192 JAPAN
E-mail. s-renkei@med.kawasaki-m.ac.jp
提供申込書類(英) Order Form(C-0005.pdf)   Approval Form(C-0006.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   承諾書C-0002.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください（詳細）。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 知的財産権 Kawasaki University of Medical Welfare (Japan)
寄託者 TOHYAMA, Kaoru
樹立者 TOHYAMA, Kaoru
寄託日 2022
別名 MDSL
クローニング（寄託者） No
動物種 _human < Mammals
属名 Homo
種名 sapiens
人種 Japanese
性別 Male
齢 54 years
採取組織 bone marrow
原発組織 bone marrow
病名 myelodysplastic syndrome (MDS)
腫瘍 MDS-EB1 stage from MDS-RS
細胞分類 cancer
遺伝子改変 non-recombinant
初代培養日 1991
メモ_1 splice donor site mutation of TP53 (c.672+1G>A; homozygous; COSM6906) NRAS (G12A) mutation (heterozygous; COSM565) CEBPA (Q311stop) mutation (heterozygous; COSM29221) HIST1H3C (K27M) mutation (heterozygous; COSM1580151) in a part of the cells
細胞寿命 infinite
細胞形態 lymphocyte-like
分化機能特性 Whole cells retain immature blastic features and differentiation-induction is successful at present.
その他要求性 IL-3-dependent
接触阻害 No
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Suspension cells Suspension cells
培養方法 General Guidelines for Culturing Suspension Cells, 浮遊細胞の培養に関する一般的な注意(Japanese)
培地 See : How_to_culture_MDS-L_and_MDS-L-2007.pdf RPMI1640 + 10% FBS + 50μM 2-mercaptoethanol + 20ng/ml hIL-3
抗生物質 Free
継代方法 See : How_to_culture_MDS-L_and_MDS-L-2007.pdf dilution
播種細胞数 1.0x10 5 cells/ml
継代密度 1 : 4-5 split
継代・培地交換頻度 Subculture : 2 times/week
培養最適温度 37 ℃ 37 ℃
二酸化炭素濃度 5 % 5 %
凍結培地 10%DMSO / 40%FCS / 50% RPMI1640 medium 50% RPMI1640 medium + 40%FBS + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ/アコレプラズマ (-)
動物種PCR OK
ウィルス（HIV) Undetected
ウィルス（HTLV-1) (-)
ウィルス（EBV) (-)
染色体検査 Main karyotype: 49, XY, +1, der(5)t(5;19), -7, +8, -12, der(13)t(7;13), der(14)t(12;14), der(15)t(15;15), -17, +19, +20, der(21)t(15;21), der(22)t(11;22).
細胞表面抗原 CD13, CD33:strongly positive; CD34: positive; HLA-DR: positive. A very small fraction may be positive for CD7 and CD41.
倍加時間 36-48 hr
その他 Tumorigenesis : successful in the immunodeficient mice carrying human IL-3 gene
メモ_2 FCS や IL-3 のロットにより増殖不良となることがある。
個体識別検査 OK
その他の細胞情報 寄託時情報ロット情報
How_to_culture_MDS-L_and_MDS-L-2007.pdf
文献情報 Reference(英) 33件
Reference(日) 0件
利用者成果(英) 0件
利用者成果(日) 0件

トップへページトップへ
Reference(英)
17049  Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, Helmenstine E, Rajkhowa T, Paun BC, Bonifant C, Dalton WB, Gondek LP, Moliterno AR, Levis MJ, Ghiaur G, Jones RJ.  The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia  Sci Adv  2022  8(7):eabl8952  PubMed ID: 35179961   DOI: 10.1126/sciadv.abl8952
17050  Shafiee S, Gelebart P, Popa M, Hellesøy M, Hovland R, Brendsdal Forthun R, Lee J, Tohyama K, Molven A, Parekkadan B, Tore Gjertsen B, Olsnes Kittang A, McCormack E.  Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line  Br J Haematol  2021  193(2):415-419  PubMed ID: 33686650   DOI: 10.1111/bjh.17372
17073  Kayamori K, Nagai Y, Zhong C, Kaito S, Shinoda D, Koide S, Kuribayashi W, Oshima M, Nakajima-Takagi Y, Yamashita M, Mimura N, Becker HJ, Izawa K, Yamazaki S, Iwano S, Miyawaki A, Ito R, Tohyama K, Lennox W, Sheedy J, Weetall M, Sakaida E, Yokote K, Iwama A.  DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes  Blood Add  2021  5(2):438-450  PubMed ID: 33496740   DOI: 10.1182/bloodadvances.2020001461
17074  Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y, Fukuda-Kurahashi Y, Yoshida-Sakai N, Hattori N, Hayashi Y, Kawaguchi A, Tohyama K, Okada S, Harada H, Ushijima T, Kimura S.  Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects  Mol Cancer Ther  2021  20(8):1412-1421  PubMed ID: 34045225   DOI: 10.1158/1535-7163.MCT-20-1125
17075  Kurozumi N, Tsujioka T, Ouchida M, Sakakibara K, Nakahara T, Suemori SI, Takeuchi M, Kitanaka A, Shibakura M, Tohyama K.  VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines  Cancer Sci  2021  112(8):3302-3313  PubMed ID: 34032336   DOI: 10.1111/cas.14982
17076  Zhang Z, Jia Y, Xv F, Song LX, Shi L, Guo J, Chang CK.  Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation  Front Genet  2021  11:603956  PubMed ID: 33584800   DOI: 10.3389/fgene.2020.603956
17077  Liu J, Liang L, Li X, Peng YL, Zhang J, Wang XL, Liu J, Nie L.  AICAR suppresses cell proliferation and synergizes with decitabine in myelodysplastic syndrome via DNA damage induction  Biotechnol Lett  2021  43(6):1131-1142  PubMed ID: 33788127   DOI: 10.1007/s10529-021-03112-2
17067  Zhong C, Kayamori K, Koide S, Shinoda D, Oshima M, Nakajima-Takagi Y, Nagai Y, Mimura N, Sakaida E, Yamazaki S, Iwano S, Miyawaki A, Ito R, Tohyama K, Yamaguchi K, Furukawa Y, Lennox W, Sheedy J, Weetall M, Iwama A.  Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome  Cancer Sci  2020  111(12):4336-4347.  PubMed ID: 33037737   DOI: 10.1111/cas.14684
17068  Su YL, Wang X, Mann M, Adamus TP, Wang D, Moreira DF, Zhang Z, Ouyang C, He X, Zhang B, Swiderski PM, Forman SJ, Baltimore D, Li L, Marcucci G, Boldin MP, Kortylewski M.  Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo  Blood  2020  135(3):167-180  PubMed ID: 31805184   DOI: 10.1182/blood.2019002045
17069  He X, Dou A, Feng S, Roman-Rivera A, Hawkins C, Lawley L, Zhang J, Wunderlich M, Mizukawa B, Halene S, Patel A, Fang J.  Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro  Exp Hematol  2020  86:21-27.e2  PubMed ID: 32437909   DOI: 10.1016/j.exphem.2020.05.001
17070  Huang F, Sun J, Chen W, He X, Zhu Y, Dong H, Wang H, Li Z, Zhang L, Khaled S, Marcucci G, Huang J, Li L.  HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML  Aging (Albany NY)  2020  12(17):16759-16774  PubMed ID: 32726753   DOI: 10.18632/aging.103605
17071  Dou A, Fang J.  Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies  J Cell Immunol  2020  ;2(5):237-244.  PubMed ID: 32984863   DOI: 10.33696/immunology.2.049
17072  Schieber M, Marinaccio C, Bolanos LC, Haffey WD, Greis KD, Starczynowski DT, Crispino JD.  FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome  Blood Cancer J  2020  10(10):98  PubMed ID: 33024076   DOI: 10.1038/s41408-020-00362-7
17064  Murakami Y, Kimura Y, Kawahara A, Mitsuyasu S, Miyake H, Tohyama K, Endo Y, Yoshida N, Imamura Y, Watari K, Ono M, Okamura T, Kuwano M.  The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes  Oncotarget  2019  10(23):2270-2281  PubMed ID: 31040918   DOI: 10.18632/oncotarget.26784
17065  Sakakibara K, Tsujioka T, Kida JI, Kurozumi N, Nakahara T, Suemori SI, Kitanaka A, Arao Y, Tohyama K.  Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway  Int J Hematol  2019  110(2):213-227.  PubMed ID: 31129802   DOI: 10.1007/s12185-019-02667-1
17066  Kam AYF, Piryani SO, McCall CM, Park HS, Rizzieri DA, Doan PL.  Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome  Clin Cancer Res  2019  25(13):4155-4167  PubMed ID: 30952643   DOI: 10.1158/1078-0432.CCR-18-3517
17048  Kida JI, Tsujioka T, Suemori SI, Okamoto S, Sakakibara K, Takahata T, Yamauchi T, Kitanaka A, Tohyama Y, Tohyama K.  An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS  Leukemia  2018  32(8):1846-1850  PubMed ID: 29955132   DOI: 10.1038/s41375-018-0189-7
17062  Sun J, He X, Zhu Y, Ding Z, Dong H, Feng Y, Du J, Wang H, Wu X, Zhang L, Yu X, Lin A, McDonald T, Zhao D, Wu H, Hua WK, Zhang B, Feng L, Tohyama K, Bhatia R, Oberdoerffer P, Chung YJ, Aplan PD, Boultwood J, Pellagatti A, Khaled S, Kortylewski M, Pichiorri F, Kuo YH, Carlesso N, Marcucci G, Jin H, Li L.  SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function  Cell Stem Cell  2018  23(3):355-369.e9  PubMed ID: 30146412   DOI: 10.1016/j.stem.2018.07.018
17063  Ruppenthal S, Kleiner H, Nolte F, Fabarius A, Hofmann WK, Nowak D, Seifarth W.  Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS  PLoS One  2018  13(1):e0191734  PubMed ID: 29370237   DOI: 10.1371/journal.pone.0191734
17060  Li L, Sheng Y, Li W, Hu C, Mittal N, Tohyama K, Seba A, Zhao YY, Ozer H, Zhu T, Qian Z.  β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q)  Cancer Res  2017  77(15):4116-4126  PubMed ID: 28611040   DOI: 10.1158/0008-5472.CAN-17-0202
17061  Oben KZ, Alhakeem SS, McKenna MK, Brandon JA, Mani R, Noothi SK, Jinpeng L, Akunuru S, Dhar SK, Singh IP, Liang Y, Wang C, Abdel-Latif A, Stills HF Jr, St Clair DK, Geiger H, Muthusamy N, Tohyama K, Gupta RC, Bondada S.  Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A  Oncotarget  2017  8(44):77436-77452  PubMed ID: 29100399   DOI: 10.18632/oncotarget.20497
17057  Okamoto S, Tsujioka T, Suemori S, Kida J, Kondo T, Tohyama Y, Tohyama K.  Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression  Cancer Sci  2016  107(9):1302-14  PubMed ID: 27311589   DOI: 10.1111/cas.12988
17058  Fang J, Liu X, Bolanos L, Barker B, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Grimes HL, Fontanillo C, Komurov K, MacBeth K, Starczynowski DT.  A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes  Nat Med  2016  22(7):727-34  PubMed ID: 27294874   DOI: 10.1038/nm.4127
17059  Zhang C, Suo J, Katayama H, Wei Y, Garcia-Manero G, Hanash S.  Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines  Clin Proteomics  2016  13:14  PubMed ID: 27382363   DOI: 10.1186/s12014-016-9115-z
17054  Hyoda T, Tsujioka T, Nakahara T, Suemori S, Okamoto S, Kataoka M, Tohyama K.  Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest  Cancer Sci  2015  106(3):287-93  PubMed ID: 25580850   DOI: 10.1111/cas.12605
17055  Tsujioka T, Yokoi A, Itano Y, Takahashi K, Ouchida M, Okamoto S, Kondo T, Suemori S, Tohyama Y, Tohyama K.  Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells  Sci Rep  2015  5:16709  PubMed ID: 26577244   DOI: 10.1038/srep16709
17056  Tibes R, Al-Kali A, Oliver GR, Delman DH, Hansen N, Bhagavatula K, Mohan J, Rakhshan F, Wood T, Foran JM, Mesa RA, Bogenberger JM.  The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia  J Hematol Oncol  2015  8:114  PubMed ID: 26483188   DOI: 10.1186/s13045-015-0211-8
17052  Hu XM, Yuan B, Tanaka S, Song MM, Onda K, Tohyama K, Zhou AX, Toyoda H, Hirano T.  Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines  Hematology  2014  19(6):352-60  PubMed ID: 24192507   DOI: 10.1179/1607845413Y.0000000138
17053  Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT.  An MDS xenograft model utilizing a patient-derived cell line  Leukemia  2014  28(5):1142-5  PubMed ID: 24326684   DOI: 10.1038/leu.2013.372
17047  Tsujioka T, Yokoi A, Uesugi M, Kishimoto M, Tochigi A, Suemori S, Tohyama Y, Tohyama K.  Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines  Exp Hematol  2013  41(2):189-97  PubMed ID: 23085465   DOI: 10.1016/j.exphem.2012.10.006
17046  Tsujioka T, Matsuoka A, Tohyama Y, Tohyama K.  Approach to new therapeutics: investigation by the use of MDS-derived cell lines  Curr Pharm Des  2012  18(22):3204-14  PubMed ID: 22571700   DOI: 10.2174/1381612811209023204
17051  Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T, Tasaka T, Tohyama Y, Tohyama K.  Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis  Leukemia  2010  24(4):748-55  PubMed ID: 20130600   DOI: 10.1038/leu.2009.296
17043  Tohyama K.  Human factor-dependent leukemia cell lines  Int J Hematol  1997  65(4):309-17  PubMed ID: 9195772   DOI: 10.1016/s0925-5710(96)00563-4

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)

トップへページトップへ
利用者成果(日)


戻る 戻る 理研トップページへ